- Home
- CERO vs EVOK Comparison
CERO vs EVOK Comparison
Compare CERO & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- EVOK
- Stock Information
- Founded
- CERO 2017
- EVOK 2007
- Country
- CERO United States
- EVOK United States
- Employees
- CERO N/A
- EVOK N/A
- Industry
- CERO
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- EVOK Health Care
- Exchange
- CERO Nasdaq
- EVOK Nasdaq
- Market Cap
- CERO 8.4M
- EVOK 7.1M
- IPO Year
- CERO N/A
- EVOK 2013
- Fundamental
- Price
- CERO $1.92
- EVOK $4.75
- Analyst Decision
- CERO
- EVOK
- Analyst Count
- CERO 0
- EVOK 0
- Target Price
- CERO N/A
- EVOK N/A
- AVG Volume (30 Days)
- CERO 787.1K
- EVOK 10.0K
- Earning Date
- CERO 02-20-2025
- EVOK 03-13-2025
- Dividend Yield
- CERO N/A
- EVOK N/A
- EPS Growth
- CERO N/A
- EVOK N/A
- EPS
- CERO N/A
- EVOK N/A
- Revenue
- CERO N/A
- EVOK $8,617,036.00
- Revenue This Year
- CERO N/A
- EVOK $97.35
- Revenue Next Year
- CERO N/A
- EVOK $99.52
- P/E Ratio
- CERO N/A
- EVOK N/A
- Revenue Growth
- CERO N/A
- EVOK 100.35
- 52 Week Low
- CERO $1.76
- EVOK $3.54
- 52 Week High
- CERO $1,238.00
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- CERO 33.62
- EVOK 53.11
- Support Level
- CERO $1.77
- EVOK $4.68
- Resistance Level
- CERO $2.22
- EVOK $5.00
- Average True Range (ATR)
- CERO 0.36
- EVOK 0.28
- MACD
- CERO 0.29
- EVOK 0.03
- Stochastic Oscillator
- CERO 11.27
- EVOK 50.00
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.